Nanocovax - Wikipedia
Nanocovax, researched and developed by Nanogen, consists of recombinant spike-protein subunits bound to silica nanoparticles. A Phase 2 study of Nanocovax was successfully conducted with 560 subjects and robust immune responses, including a strong IgG response as measured by the sCOVG test were observed in all vaccinated subjects.
Safety and immunogenicity of Nanocovax, a SARS-CoV-2 recombinant spike ...
Nanocovax, developed by startup Nanogen Pharmaceutical Biotechnology in collaboration with Vietnam Military Medical University, started the final trials on Thursday, the company said.
Safety and immunogenicity of Nanocovax, a SARS-CoV-2 ... - PubMed
Nanocovax induced high levels of anti-S antibody (Ab). Neutralising antibody titres were evaluated by micro-neutralisation (against the original (Wuhan) strain and the Alpha variant) and surrogate virus neutralisation test. Importantly, Nanocovax conferred a remarkable protection against SARS-CoV-2 infection in hamster challenge model.6
A Comprehensive Review of the Protein Subunit Vaccines Against COVID-19
ABSTRACT. Background Nanocovax is a recombinant severe acute respiratory syndrome coronavirus 2 subunit vaccine composed of full-length prefusion stabilized recombinant SARS-CoV-2 spike glycoproteins (S-2P) and aluminum hydroxide adjuvant. Methods We conducted a dose-escalation, open label trial (phase 1) and a randomized, double-blind, ...
PDF Introduction to Nanocovax, Vietnamese Covid Vaccine
In case of emergency approval, Vietnam would be able to produce 100 million doses per year. Nanocovax of Nanogen Pharmaceutical Biotechnology JSC is currently Vietnam's Covid-19 vaccine with the most potential. This vaccine is now in the third phase of trial, with the participation of 1,000 volunteers.
Phase 1/2 trial results for Nanocovax, protein subunit SARS-CoV-2 ...
Nanocovax is a subunit vaccine, developed and manufactured at Nanogen Pharmaceutical Biotechnology JSC., containing full-length prefusion stabilized recombinant SARS-CoV-2 S glycoproteins and aluminium hydroxide adjuvant. In rodent and monkey models, Nanocovax induced high levels of anti-S antibody (Ab).
PDF Safety and immunogenicity of Nanocovax, a SARS-CoV-2 recombinant spike ...
PMID: 35602004. PMCID: PMC9108376. DOI: Abstract. Background: Nanocovax is a recombinant severe acute respiratory syndrome coronavirus 2 subunit vaccine composed of full-length prefusion stabilized recombinant SARS-CoV-2 spike glycoproteins (S-2P) and aluminium hydroxide adjuvant.
Preclinical Immune Response and Safety Evaluation of the Protein ...
In early August, India's Vekaria Pharmaceutical Group inked a deal with Nanogen to supply Nanocovax to the world's second-most populous country. The deals are expected to help the Vietnamese-made COVID-19 vaccine soon join global supply chain, easing the global shortfall of COVID-19 vaccines.
Safety and Immunogenicity of Nanocovax, a SARS-CoV-2 ... - medRxiv
This is a phase 3, adaptive, multicenter, randomized, double-blind, placebo control study to evaluate the safety, immunogenicity, and efficacy of the Nanocovax vaccine against COVID-19 in volunteer subjects 18 years of age and older. Age stratified as 18-45, 45-60, and > 60 years of age.
COVID-19 Vaccine Candidate Nanocovax Induces Robust Immunity
Conclusions Up to 42 days, Nanocovax vaccine was safe, well tolerated and induced robust immune responses. We propose using Nanocovax 25 mcg for Phase 3 to evaluate the vaccine efficacy. (Research funded by Nanogen Pharmaceutical Biotechnology JSC., and the Ministry of Science and Technology of Vietnam; ClinicalTrials.gov number, NCT04683484.)